Question 1

What is the catalog number for (2E) -4-Phenyl-2-butenoic acid?

Accepted Answer

The catalog number for (2E) -4-Phenyl-2-butenoic acid is FP181083.

Question 2

What sizes are available for (2E) -4-Phenyl-2-butenoic acid?

Accepted Answer

(2E) -4-Phenyl-2-butenoic acid is available in the following size(s): 100 mg, 500 mg, 1000 mg, 2000 mg.

Question 3

How many pack sizes does (2E) -4-Phenyl-2-butenoic acid come in?

Accepted Answer

(2E) -4-Phenyl-2-butenoic acid is available in 4 different pack sizes.

Question 4

Is (2E) -4-Phenyl-2-butenoic acid in stock?

Accepted Answer

(2E) -4-Phenyl-2-butenoic acid is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What dilution range is recommended for immunohistochemistry (IHC) with this antibody?

Accepted Answer

A starting IHC dilution range is listed on the datasheet, but should be optimized for your specific tissue type and staining protocol.

Question 6

Can I request a Safety Data Sheet (SDS) for this product?

Accepted Answer

Yes, safety data sheets are available for hazardous or chemically classified products and can be provided on request or downloaded from the product page.

Question 7

Can this product be used for co-immunoprecipitation (Co-IP)?

Accepted Answer

Suitability for Co-IP depends on the specific antibody and is noted under validated applications on the datasheet. If it isn’t listed, contact our technical support team for guidance based on your target and sample type.

(2E) -4-Phenyl-2-butenoic acid

Product Specifications

CAS Number

Smiles

Molecular Formula

Molecular Weight

Controlled

Available Sizes

Frequently Asked Questions

Explore Other Products

tert-Butyl 6-Hydroxy-2-azaspiro[3.3]heptane-2-carboxylate

Retinoic Acid Receptor gamma (RARG) Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI3G1]

RPL6 (NM_001024662) Human Over-expression Lysate

Neurofilament (NF-H) (RT-97), CF647 conjugate, 0.1mg/mL

3,3'-Diacetyl-cis-azobenzene

ADM2 Human Gene Knockout Kit (CRISPR)